Therapeutic Role of Low Molecular Weight Heparin and Fat-Soluble Vitamins in Pregnancy-Associated Prethrombotic Conditions

Pregnancy represents a unique physiological state characterized by a hypercoagulable environment designed to support fetal development. This natural shift significantly elevates the risk of venous thromboembolism (VTE) and other prethrombotic conditions, contributing substantially to maternal and fetal morbidity and mortality. Understanding these mechanisms is critical for laboratory research into metabolic regulation and coagulation pathways during gestation.

The authors review current evidence regarding the pathophysiology of pregnancy-associated prethrombotic conditions. While low molecular weight heparin (LMWH) remains the cornerstone of prophylaxis and treatment due to its established efficacy and safety profile, emerging evidence suggests that thrombosis in pregnancy is a multifactorial process. The study highlights interconnected pathways involving endothelial dysfunction, inflammation, oxidative stress, and impaired placental development.

These findings indicate limitations of anticoagulation alone in addressing the full spectrum of disease mechanisms. Fat-soluble vitamins, including vitamins D, K, E, and A, play critical roles in regulating vascular integrity, immune responses, oxidative balance, and coagulation pathways. Deficiencies or imbalances in these vitamins have been associated with adverse pregnancy outcomes such as preeclampsia, intrauterine growth restriction, recurrent pregnancy loss, and preterm birth.

Mechanistically, these vitamins modulate upstream processes that contribute to thrombotic risk, complementing the downstream anticoagulant effects of LMWH. This review synthesizes current evidence on the therapeutic role of LMWH and the biological functions of fat-soluble vitamins in maternal–fetal health. The authors propose a synergistic model in which these interventions act through complementary mechanisms to target both the causes and consequences of thrombosis.

Despite a strong mechanistic rationale, clinical data evaluating combined LMWH and vitamin-based strategies remain limited. Future research should focus on randomized controlled trials, biomarker-guided approaches, and precision medicine strategies to optimize treatment. The integration of anticoagulant therapy with targeted nutritional modulation represents a promising avenue for improving pregnancy outcomes and advancing the management of thrombotic disorders in maternal–fetal medicine.